ATE455300T1 - Verfahren und zusammensetzungen zum auslösen einer immunantwort - Google Patents
Verfahren und zusammensetzungen zum auslösen einer immunantwortInfo
- Publication number
- ATE455300T1 ATE455300T1 AT02805706T AT02805706T ATE455300T1 AT E455300 T1 ATE455300 T1 AT E455300T1 AT 02805706 T AT02805706 T AT 02805706T AT 02805706 T AT02805706 T AT 02805706T AT E455300 T1 ATE455300 T1 AT E455300T1
- Authority
- AT
- Austria
- Prior art keywords
- ckbeta8
- compositions
- discovered
- inventors
- methods
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 abstract 4
- 101710091942 N-formyl peptide receptor 2 Proteins 0.000 abstract 4
- ULUOXCRNSRVJPE-MJRHPTFMSA-N 2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]propanoyl]amino]acetic acid Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(O)=O)C1=CN=CN1 ULUOXCRNSRVJPE-MJRHPTFMSA-N 0.000 abstract 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 210000001616 monocyte Anatomy 0.000 abstract 2
- 210000000440 neutrophil Anatomy 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000005714 functional activity Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/141,508 US20030215460A1 (en) | 2002-05-07 | 2002-05-07 | Methods and compositions for inducing an immune response |
| PCT/US2002/036206 WO2003096017A1 (en) | 2002-05-07 | 2002-10-21 | Methods and compositions for inducing an immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE455300T1 true ATE455300T1 (de) | 2010-01-15 |
Family
ID=29418406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02805706T ATE455300T1 (de) | 2002-05-07 | 2002-10-21 | Verfahren und zusammensetzungen zum auslösen einer immunantwort |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20030215460A1 (https=) |
| EP (1) | EP1499886B1 (https=) |
| JP (1) | JP4299777B2 (https=) |
| KR (1) | KR100943825B1 (https=) |
| CN (1) | CN1639569B (https=) |
| AT (1) | ATE455300T1 (https=) |
| AU (1) | AU2002365437B2 (https=) |
| CA (1) | CA2484607A1 (https=) |
| DE (1) | DE60235122D1 (https=) |
| DK (1) | DK1499886T3 (https=) |
| ES (1) | ES2338308T3 (https=) |
| WO (1) | WO2003096017A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2554370A1 (en) * | 2004-01-26 | 2005-08-25 | Brett Premack | Compositions and methods of use of w-peptides |
| EP1799096A2 (en) * | 2004-09-30 | 2007-06-27 | Boston Scientific Scimed, Inc. | System and method of obstruction removal |
| US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| US8221995B2 (en) * | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| AU2010270313B2 (en) * | 2009-07-10 | 2014-05-22 | Transgene Sa | Biomarker for selecting patients and related methods |
| KR101249041B1 (ko) | 2010-04-28 | 2013-03-29 | 포항공과대학교 산학협력단 | 결합조직 성장인자를 이용한 약학적 조성물 |
| DK3122375T3 (da) | 2014-03-28 | 2021-05-25 | Univ Washington Through Its Center For Commercialization | Vacciner mod bryst- og ovariecancer |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| CN107375922B (zh) * | 2017-07-20 | 2020-06-09 | 南京农业大学 | 一种水溶性复合免疫佐剂及猪圆环病毒病疫苗 |
| JP2019116454A (ja) * | 2017-12-27 | 2019-07-18 | 国立大学法人帯広畜産大学 | アジュバント |
| CN112263674A (zh) * | 2020-11-09 | 2021-01-26 | 天津农学院 | 一种猪3型链球菌荚膜多糖亚单位疫苗及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5284753A (en) | 1991-03-20 | 1994-02-08 | Neuro Probe, Inc. | Multiple-site chemotactic test apparatus and method |
| PT633929E (pt) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| US6001606A (en) * | 1994-03-08 | 1999-12-14 | Human Genome Sciences, Inc. | Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby |
| IL113610A0 (en) | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
| US5874211A (en) | 1995-04-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Chemokine expressed in eosinophils |
| EA199800352A1 (ru) * | 1995-09-29 | 1998-12-24 | Смитклайн Бичам Корпорейшн | ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА |
| KR20030097607A (ko) * | 1996-09-30 | 2003-12-31 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 골수양 선조 세포 억제 인자-1(ｍｐｉｆ-1)를 이용하여질병 상태를 치료하기 위한 치료 조성물 및 치료 방법 |
| DE19913707A1 (de) * | 1999-03-26 | 2000-10-05 | Privates Inst Bioserv Gmbh | Immunadsorber zur Sepsistherapie |
| MXPA02003801A (es) * | 1999-10-14 | 2002-10-23 | Human Genome Sciences Inc | Metodos para tratar o prevenir dano en celulas, tejidos y organos utilizando el factor inhibitorio progenitor de miloide-1 (mpfi-1) humano. |
| US20030096260A1 (en) * | 2001-10-09 | 2003-05-22 | Zhenhua Miao | Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
-
2002
- 2002-05-07 US US10/141,508 patent/US20030215460A1/en not_active Abandoned
- 2002-10-21 ES ES02805706T patent/ES2338308T3/es not_active Expired - Lifetime
- 2002-10-21 AU AU2002365437A patent/AU2002365437B2/en not_active Ceased
- 2002-10-21 DK DK02805706.5T patent/DK1499886T3/da active
- 2002-10-21 AT AT02805706T patent/ATE455300T1/de active
- 2002-10-21 WO PCT/US2002/036206 patent/WO2003096017A1/en not_active Ceased
- 2002-10-21 KR KR1020047017801A patent/KR100943825B1/ko not_active Expired - Fee Related
- 2002-10-21 JP JP2004503957A patent/JP4299777B2/ja not_active Expired - Fee Related
- 2002-10-21 DE DE60235122T patent/DE60235122D1/de not_active Expired - Lifetime
- 2002-10-21 CN CN028292847A patent/CN1639569B/zh not_active Expired - Fee Related
- 2002-10-21 EP EP02805706A patent/EP1499886B1/en not_active Expired - Lifetime
- 2002-10-21 CA CA002484607A patent/CA2484607A1/en not_active Abandoned
-
2005
- 2005-07-05 US US11/175,003 patent/US8637043B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2338308T3 (es) | 2010-05-06 |
| JP4299777B2 (ja) | 2009-07-22 |
| CN1639569B (zh) | 2012-09-05 |
| US20030215460A1 (en) | 2003-11-20 |
| KR100943825B1 (ko) | 2010-02-25 |
| US8637043B2 (en) | 2014-01-28 |
| AU2002365437A1 (en) | 2003-11-11 |
| DE60235122D1 (de) | 2010-03-04 |
| JP2005524719A (ja) | 2005-08-18 |
| KR20050027089A (ko) | 2005-03-17 |
| AU2002365437B2 (en) | 2010-06-03 |
| US20060034863A1 (en) | 2006-02-16 |
| CA2484607A1 (en) | 2003-11-20 |
| WO2003096017A1 (en) | 2003-11-20 |
| EP1499886B1 (en) | 2010-01-13 |
| CN1639569A (zh) | 2005-07-13 |
| DK1499886T3 (da) | 2010-05-25 |
| EP1499886A1 (en) | 2005-01-26 |
| EP1499886A4 (en) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE455300T1 (de) | Verfahren und zusammensetzungen zum auslösen einer immunantwort | |
| Triebel | LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination | |
| Agger et al. | Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31 | |
| IL138424A (en) | Covalently reactive antigen analogs and pharmaceutical compositions containing the same | |
| HUP0203567A2 (hu) | APRIL-receptor (BCMA) és alkalmazásai | |
| SG196688A1 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
| Kreiter et al. | FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines | |
| WO2007028047A3 (en) | Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy | |
| TW202513581A (zh) | 介白素-2/介白素-2受體阿法融合蛋白及其使用方法 | |
| EP1536820A4 (en) | CANCER THERAPY WITH WHOLE GLUCAN PARTICLES AND ANTIQUE RPARS | |
| HUP0401591A2 (hu) | Új receptor-nukleinsavak és- polipeptidek | |
| ATE315405T1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
| ATE279517T1 (de) | Il-17 receptor | |
| NO20001104D0 (no) | Humaniserte antistoff mot humant gp39, sammensetninger inneholdende slike samt terapeutiske anvendelser derav | |
| WO2003050241A3 (en) | Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation | |
| PL377337A1 (pl) | Humanizowane przeciwciało (H14.18) z mysiego przeciwciała 14.18 wiążące GD2 oraz jego połączenie z IL-2 | |
| WO2003106498A3 (en) | Ox40 (=cd134) receptor agonistic and therapeutic use | |
| TR200103012T2 (tr) | Yeni kompozisyonlar | |
| EP1434854A4 (en) | COMPOSITIONS USEFUL AS LIGANDS OF THE RECEPTOR TYPE RECEPTOR OF FORMY PEPTIDES AND METHODS OF USE THEREOF | |
| WO2006105993A3 (en) | Method for shielding functional sites or epitopes on proteins | |
| ATE267213T1 (de) | Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind | |
| NO991926D0 (no) | Oppl°selige lymfotoksin-<beta> reseptorer, anti-lymfotoksinreseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer | |
| EP1594533A4 (en) | Antibody vaccine conjugates and uses therefor | |
| WO2006085895A3 (en) | Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies | |
| DE60109922D1 (de) | Therapeutische verbindungen gegen eierstockkrebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1499886 Country of ref document: EP |